{
    "action": "final",
    "content": "## Most Important Metric and Category\n\n**Most Important Metric:** Adverse event rate (adverse events per subject)  \n**Most Important Category:** Treatment arm (ACTARMCD/ACTARM)\n\nIn clinical trial safety monitoring, the adverse event rate is the primary metric for assessing treatment safety and tolerability. Treatment arm is the fundamental stratification for any trial analysis, as comparing safety profiles across treatment groups drives regulatory decisions about whether to advance a drug candidate.\n\n## Adverse Event Rate Variation Across Treatment Arms\n\nThe data reveals a clear dose-response relationship in adverse event rates:\n\n- **Xanomeline High Dose**: 6.23 adverse events per subject (436 events across 70 subjects)\n- **Xanomeline Low Dose**: 5.28 adverse events per subject (454 events across 86 subjects)  \n- **Placebo**: 4.36 adverse events per subject (301 events across 69 subjects)\n\nThe high-dose arm shows **43% more adverse events per subject** than placebo (6.23 vs 4.36), while the low-dose arm shows a 21% increase. This dose-dependent safety signal is a critical finding: higher Xanomeline doses are associated with more adverse events, which would inform dose selection decisions for subsequent trial phases.\n\nNotably, 254 subjects were randomized to active treatment or placebo (excluding the 52 screen failures), with 225 subjects (88%) experiencing at least one adverse event during the trial. The consistency of adverse event occurrence across arms—with 86-100% of subjects in each arm reporting events—indicates this is a well-monitored trial with comprehensive safety capture.\n\n*Analysis based on SQL queries joining raw.adsl (subject demographics and treatment assignments) with raw.ae (adverse event records) on USUBJID.*",
    "charts": [
        {
            "kind": "bar",
            "x": "ACTARM",
            "series": [
                "aes_per_subject"
            ],
            "title": "Adverse Events Per Subject by Treatment Arm"
        }
    ]
}